Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKC876 in relapsed/refractory indolent non-Hodgkin lymphoma
CTR20220025Phase 2Active
- Sponsor
- Fosun Kairos
- Start
- Jun 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in indolent lymphoma, sponsored by Fosun Kairos. Started Jun 2022; status: active.
02
Drugs
axicabtagene ciloleucel
03
Conditions
indolent lymphoma
Beyond the preview
Go deeper on CTR20220025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220025.